Trial ID or NCT#

NCT02867384

Status

RECRUITING

Purpose

The primary objective of this study is to prevent chronic graft versus host disease in stem cell transplant patients. The drug being studied will be administered in the hopes of preventing cGVHD, and the use of steroids to treat it.

Official Title

A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

David Miklos, M.D., Ph.D.
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Hematologist, Medical oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Robert Negrin, M.D.
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation)
Robert Lowsky, MD
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Andrew R. Rezvani, M.D.
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Medical oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Lori Muffly, MD, MS
Hematologist, Blood and marrow transplant specialist
Clinical Assistant Professor, Medicine - Blood & Marrow Transplantation
D. Kathryn Tierney

Contact us to find out if this trial is right for you.

CONTACT

Juliana Craig
(650) 725-8130